AAT deficiency newco Apic Bio launches

Gene therapy company Apic Bio Inc. (Cambridge, Mass.) launched Tuesday with an undisclosed investment from the Alpha-1 Foundation and private investor Ed Krapels, who has alpha-1 antitrypsin (AAT; A1AT; SERPINA1) deficiency.

The company said its lead AAT deficiency candidate, APB-101, has achieved preclinical proof of concept with efficacy shown in vitro and in vivo, and is currently undergoing preclinical toxicology studies in non-human primates...